webinar register page

Pain R&D: Plenty of pain to go around, but who’s making gains?
The pipeline for new pain drugs has grown perilously thin in recent years with a slate of key clinical trial failures. Only a few small players are still actively engaged in developing new therapies to replace the aging therapeutics that now dominate the market, especially after Pfizer’s last setback on an anti-NGF drug, finally closing that chapter of new drug development. Endpoints News will take a close look at the conditions that are limiting access to new drugs and the intense medical need to find drugs that can do a better job for an aging population. Lei L.ei Wu will dig in to explain what’s happening here.


* Required information